immucor.jpg
Immucor and Pirche announce multi-year partnership
04 oct. 2022 08h04 HE | Immucor, Inc.
NORCROSS, Ga. and BERLIN, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Immucor, Inc., a global leader in transfusion and transplantation diagnostics, and Pirche AG, the global leader in AI-powered molecular...
Global Organ Transplant Market Report 2022: Rising Need for Innovative Tissue Transplantation Products and Organ Transplantation to Treat Organ Failure Propelling Sector
06 sept. 2022 05h23 HE | Research and Markets
Dublin, Sept. 06, 2022 (GLOBE NEWSWIRE) -- The "Global Organ Transplant Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.A major element driving...
Surreal Photography Exhibit Brings Awareness
01 sept. 2022 09h30 HE | Texas Organ Sharing Alliance
Austin, TX, Sept. 01, 2022 (GLOBE NEWSWIRE) -- AUSTIN, TX (September 1, 2022) – A Central Texas couple who create fine-art surreal photographs is collaborating with the Austin-Bergstrom...
eledon-logo-1230.png
Eledon Pharmaceuticals to Participate in Two Upcoming Investor Conferences
29 août 2022 08h00 HE | Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming investor...
The Worldwide Organ Transplant Diagnostics Industry is Expected to Reach $6 Billion by 2031
12 août 2022 07h08 HE | Research and Markets
Dublin, Aug. 12, 2022 (GLOBE NEWSWIRE) -- The "Global Organ Transplant Diagnostics Market 2021-2031 by Offering, Transplant, Application, Technology, End User, and Region: Trend Forecast and Growth...
eledon-logo-1230.png
Eledon Pharmaceuticals Reports Second Quarter 2022 Operating and Financial Results
11 août 2022 16h01 HE | Eledon Pharmaceuticals, Inc.
Received FDA clearance of IND application for Phase 2 trial evaluating tegoprubart for the prevention of rejection in kidney transplant recipients First patient dosed in Phase 1b trial evaluating...
eledon-logo-1230.png
Eledon Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
04 août 2022 16h05 HE | Eledon Pharmaceuticals, Inc.
Management to host conference call and webcast at 4:30 pm ET IRVINE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical...
eledon-logo-1230.png
Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients
01 août 2022 05h00 HE | Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
eledon-logo-1230.png
Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation
18 juil. 2022 08h00 HE | Eledon Pharmaceuticals, Inc.
IRVINE, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
eledon-logo-1230.png
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 juin 2022 16h05 HE | Eledon Pharmaceuticals, Inc.
IRVINE, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...